Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMVAC + nivolumab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMVAC + nivolumab is a combination therapy consisting of the AMVAC chemotherapy regimen and the immune checkpoint inhibitor nivolumab. The AMVAC regimen typically includes doxorubicin (Adriamycin), methotrexate, vinblastine, and cisplatin—agents commonly used in oncology for their cytotoxic effects on rapidly dividing cancer cells. Nivolumab is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 ligands and thereby enhancing anti-tumor immune responses. This combination aims to leverage both direct cytotoxicity from chemotherapy and immunomodulation from checkpoint inhibition to improve outcomes in cancer treatment.
- Other names
- AMVAC + nivolumab
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on AMVAC + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMVAC + nivolumab.